SHANGHAI – China’s biopharmaceutical industry owes its rapid rise to several factors, including unwavering government policy and financial support, a huge market with unmet needs and a talented local work force.
SHANGHAI – For Shenogen, one of the growing number of innovative drug development companies in China, industry accolades are a welcome acknowledgement of years of hard work.
SHANGHAI – Authorities are reportedly set on charging London-based Glaxosmithkline plc’s (GSK) Chinese executives on charges of bribery and corruption following initial claims by the Chinese police in July. This would leave the beleaguered GSK free from corporate criminal prosecution, but still facing potential administrative fines, investigations from anti bribery authorities in the U.S. and the UK and a sharp decline in revenues in China.
SHANGHAI – China Resources Pharmaceutical Group (CRP) has broken ground on its ¥14 billion (US$2.3 billion) campus in Daxing Biomedical Park in Beijing.
SHANGHAI – Marking a turning point for Chinese biotechnology, a company from Sichuan province – Chengdu Institute of Biological Products Co. Ltd. (CIBP) – has earned coveted pre-qualification status from the World Health Organization (WHO) for its Japanese encephalitis (JE) vaccine. It’s the first time a Chinese vaccine maker has earned a WHO seal of approval, which opens up markets worldwide.
SHANGHAI – Marking a turning point for Chinese biotechnology, a company from Sichuan province – Chengdu Institute of Biological Products Co. Ltd. (CIBP) – has earned coveted pre-qualification status from the World Health Organization (WHO) for its Japanese encephalitis (JE) vaccine.
